Proteomics International Laboratories Ltd (ASX:PIQ) has been invited to present the latest results from its novel blood test for oesophageal adenocarcinoma at the 19th ISDE World Congress for Esophageal Diseases in Toronto, Canada, 8-10 September 2023.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce it has signed an exclusive licence agreement with Sonic Healthcare USA, a Division of Sonic Healthcare Ltd.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce it will present its potential new blood test for endometriosis at the world s leading endometriosis conference.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce results showing a significant reduction in the PromarkerD risk scores of patients with type 2 diabetes after taking the diabetes medicine canagliflozin.
Proteomics International Laboratories Ltd (ASX:PIQ) in collaboration with Janssen Research & Development have shown that treatment with Canagliflozin lowers the PromarkerD risk score for developing diabetic kidney disease.